Hoxton Planning & Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.46M Buy
1,261
+6
+0.5% +$7.08K 0.37% 51
2026
Q2
$1.51M Buy
1,255
+5
+0.4% +$5.11K 0.39% 53
2026
Q1
$1.15M Sell
1,250
-31
-2% -$31.4K 0.35% 58
2025
Q4
$1.38M Buy
1,281
+13
+1% +$12.4K 0.41% 47
2025
Q3
$967K Buy
1,268
+12
+1% +$8.93K 0.31% 61
2025
Q2
$979K Sell
1,256
-70
-5% -$54.4K 0.34% 58
2025
Q1
$1.1M Buy
1,326
+33
+3% +$27.5K 0.42% 48
2024
Q4
$998K Sell
1,293
-65
-5% -$53.8K 0.38% 47
2024
Q3
$1.2M Buy
1,358
+197
+17% +$177K 0.47% 38
2024
Q2
$1.05M Buy
1,161
+33
+3% +$26.4K 0.49% 35
2024
Q1
$878K Buy
1,128
+58
+5% +$41.3K 0.42% 43
2023
Q4
$624K Sell
1,070
-2
-0.2% -$1.17K 0.33% 53
2023
Q3
$576K Sell
1,072
-20
-2% -$10.3K 0.37% 55
2023
Q2
$512K Sell
1,092
-60
-5% -$25.2K 0.32% 62
2023
Q1
$396K Sell
1,152
-6
-0.5% -$2.02K 0.22% 93
2022
Q4
$424K Buy
+1,158
New +$411K 0.23% 92

Other funds holding LLY

Hoxton Planning & Management's LLY Position: Q3 2026 in Review

Hoxton Planning & Management increased its Eli Lilly (LLY) stake by 0.48% in Q3 2026, buying an estimated $7.08K and bringing the position to 1,261 shares worth $1.46M. The position accounts for 0.37% of the portfolio, ranked #51.

Hoxton Planning & Management first reported a position in LLY in Q4 2022 and has held it in 16 quarters since. The position peaked at $1.51M in Q2 2026. 1,227 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Hoxton Planning & Management held 1,261 shares of Eli Lilly worth $1.46M as of Q3 2026.
  • Hoxton Planning & Management bought 6 Eli Lilly shares in Q3 2026, an estimated $7.08K.
  • Eli Lilly made up 0.37% of Hoxton Planning & Management's portfolio in Q3 2026, its #51 holding.
  • Hoxton Planning & Management first reported a position in Eli Lilly in Q4 2022 and has held it in 16 quarters since.
  • Hoxton Planning & Management's Eli Lilly position peaked at $1.51M in Q2 2026.
  • 1,227 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Hoxton Planning & Management's 13F filing for Q3 2026, filed 15 Oct 2026.